Report Type : Therapy Reports

Report Category : Oncology

Report Subcategory : Multiple Myeloma or Kahler Disease

Price : 1999.00

Date : July 2021

Multiple Myeloma Global Market Landscape till 2030 : Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Multiple Myeloma or Kahler Disease:
Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body. Normal plasma cells make antibodies to help the body fight infection and disease. As the number of multiple myeloma cells increases, more antibodies are made. This can cause the blood to thicken and keep the bone marrow from making enough healthy blood cells. Multiple myeloma cells also damage and weaken the bone.

Top & Promising Drugs by Company:    

  • Bristol-Myers Squibb Co - Revlimid (lenalidomide)
  • Johnson & Johnson- Darzalex (daratumumab)
  • Johnson & Johnson- Dalinvi (daratumumab)
  • Bristol-Myers Squibb Co - Pomalyst (pomalidomide)
  • Bristol-Myers Squibb Co- Imnovid (pomalidomide)
  • Takeda Pharmaceutical Co Ltd-Velcade (bortezomib)
  • Takeda Pharmaceutical Co Ltd- Ninlaro (ixazomib citrate)
  • Amgen Inc- Kyprolis (carfilzomib)
  • Bristol-Myers Squibb Co- Abecma (idecabtagene vicleucel)
  • Sanofi- Sarclisa (isatuximab)
  • GlaxoSmithKline Plc- Blenrep (belantamab mafodotin)
  • Karyopharm Therapeutics Inc-Xpovio (selinexor)

Contact Us
+1 (404) 845-7948
info@doloxe.com
Email Us